EQS-News: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential (english)

Press/Media

Period17 Nov 2022

Media coverage

1

Media coverage